Esophagitis

This study tests an experimental drug called X842 in people with severe erosive esophagitis caused by GERD (chronic acid reflux). Participants have either severe esophagus damage (grades C or D) or milder damage that hasn't healed after 8 weeks of standard treatment. The trial co…

This study tested a new drug called BLI5100 in 1250 adults with erosive esophagitis, a condition where stomach acid damages the esophagus. Participants took either BLI5100 or a standard PPI (proton pump inhibitor) daily for up to 8 weeks to see if it healed the damage, then for 2…

This phase 2 trial tested a biologic drug called barzolvolimab in 86 adults with active eosinophilic esophagitis, a condition that causes trouble swallowing due to inflammation in the esophagus. Participants received either the drug or a placebo as a shot under the skin. The stud…

This study looks at the long-term safety of a drug called CC-93538 (cendakimab) for people with eosinophilic esophagitis, a condition that causes inflammation in the esophagus. It enrolled 367 adults and teens who had already taken part in earlier studies of the same drug. The ma…

This study checked the safety of taking BLI5100 daily for up to 12 months in 400 adults with gastroesophageal reflux disease (GERD). Participants had either non-erosive reflux disease or healed erosive esophagitis. The main goal was to track any side effects. This is a disease co…

This study looks at ways to prevent and reduce radiation esophagitis—painful inflammation of the swallowing tube—in 142 cancer patients receiving chest radiation. Researchers will test a two-step consent process and measure whether the approach cuts the need for strong painkiller…

This study enrolled 800 adults undergoing upper endoscopy to find risk factors and blood markers that could help diagnose and monitor eosinophilic esophagitis (EoE), a chronic allergic condition of the esophagus. Researchers compared people with and without EoE, collecting blood,…

This early-phase trial tested the safety and tolerability of a drug called X842 in 39 healthy adults. Participants received either single or multiple doses of X842 to see how the body handles it and what side effects may occur. The study is complete and does not aim to treat any …

This study compared a generic vonoprazan 20 mg tablet to the brand-name Voquezna in 28 healthy adults. Participants took a single dose of each under fasting conditions to see if the generic releases the same amount of drug into the bloodstream. The goal was to check bioequivalenc…